Kanwal Raghav, MD, MBBS, discusses appropriate candidates for HER2 testing and current utilization strategies for biomarker testing in mCRC.
Kanwal Raghav, MD, MBBS: For HER2 testing, as far as metastatic colorectal cancer is concerned, we identify patients based on whether we’re looking for clinical care or research trials. As far as clinical care is concerned, in most cases we look for RAS and BRAF wild-type patients who are diagnosed with metastatic disease. In the research setting, we have expanded this testing to RAS-mutated cases. Not only do we assess amplifications, which is commonly the criteria for actionable target, such as HER2, as far as the NCCN [National Comprehensive Cancer Network] Guidelines are concerned, we also look for HER2 expression levels and sometimes HER2 mutations.
We’re routinely using next-generation sequencing [NGS] in all patients with metastatic colorectal cancer. We still don’t use it in the early-stage setting, but we use it in every patient with metastatic colorectal cancer at diagnosis. Subsequently, we also use next-generation sequencing at critical points when they have progressed on therapy.
To completely optimize the use of NGS and to increase its uptake, it should be a part of quality metrics when it comes to performance. We’ve already done that. There’s precedence of this in breast cancer, in which reporting of ER [estrogen receptor], PR [progesterone receptor], and HER2 for all newly diagnosed breast cancer is a part of standard of care. NGS should become the standard of care at diagnosis for patients with metastatic colorectal cancer.
There are a lot of upcoming biomarkers in not just colorectal cancer but also other tumor types. The first step to being able to develop a targetable subset or population that you can explore in a clinical trial is identifying those biomarkers. If NGS is used as a standard of care in these patients at diagnosis, knowing very well that patients with metastatic colorectal cancer don’t have many therapy options, it will help us develop population subsets of colorectal cancer that we can successfully explore in clinical trials. If we keep identifying subsets based on what has already proven to be successful—for example, KRAS 12C and HER2 amplification are small subsets of colorectal cancer but applying NGS has allowed us to explore these in clinical trials—that’s how you can not only provide appropriate and good clinical care for them but also prepare for when those clinical care options run out.
It helps us not only identify targets that we can use drugs against in a clinical setting but also [find] patients for other biomarker-driven clinical trials in the future.
Transcript edited for clarity.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More